Bifogade filer
Vistin Pharma ASA fourth quarter report 2021
Kurs
+0,89%
Likviditet
0,63 MNOK
Kalender
| Tid* | ||
| 2024-11-06 | - | X-dag bonusutdelning VISTN 0.5 |
| 2024-11-06 | - | X-dag halvårsutdelning VISTN 0.5 |
| 2024-10-31 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-05 | - | X-dag bonusutdelning VISTN 0.5 |
| 2024-06-05 | - | X-dag halvårsutdelning VISTN 0.5 |
| 2024-05-23 | - | Årsstämma |
| 2024-04-24 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-16 | - | Bokslutskommuniké 2023 |
| 2024-01-23 | - | X-dag ordinarie utdelning VISTN 0.75 NOK |
| 2024-01-23 | - | X-dag bonusutdelning VISTN 0.75 |
| 2023-10-25 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-23 | - | X-dag ordinarie utdelning VISTN 0.00 NOK |
| 2023-05-22 | - | Årsstämma |
| 2023-04-27 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-10-26 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-24 | - | X-dag ordinarie utdelning VISTN 0.00 NOK |
| 2022-05-19 | - | Årsstämma |
| 2022-04-27 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-21 | - | X-dag ordinarie utdelning VISTN 0.50 NOK |
| 2021-05-21 | - | X-dag bonusutdelning VISTN 0.5 |
| 2021-05-20 | - | Årsstämma |
| 2021-04-23 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-19 | - | Bokslutskommuniké 2020 |
| 2020-10-30 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-24 | - | Extra Bolagsstämma 2020 |
| 2020-05-20 | - | X-dag ordinarie utdelning VISTN 1.00 NOK |
| 2020-05-19 | - | Årsstämma |
| 2020-04-23 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-10-25 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-29 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | X-dag ordinarie utdelning VISTN 0.00 NOK |
| 2019-05-22 | - | Årsstämma |
| 2019-04-25 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-19 | - | Bokslutskommuniké 2018 |
| 2018-10-25 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-30 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-25 | - | X-dag ordinarie utdelning VISTN 1.00 NOK |
| 2018-05-08 | - | Årsstämma |
| 2018-04-26 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-27 | - | Bokslutskommuniké 2017 |
| 2017-11-03 | - | X-dag bonusutdelning VISTN 7 |
| 2017-11-02 | - | Extra Bolagsstämma 2017 |
| 2017-10-27 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-31 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-26 | - | X-dag ordinarie utdelning VISTN 1.00 NOK |
| 2017-05-24 | - | Årsstämma |
| 2017-04-26 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2016-10-31 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-30 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-25 | - | X-dag ordinarie utdelning VISTN 0.60 NOK |
| 2016-05-24 | - | Årsstämma |
| 2016-04-28 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-23 | - | Bokslutskommuniké 2015 |
| 2015-10-29 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-26 | - | Kvartalsrapport 2015-Q2 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Oslo, Norway, 17th of February 2022
Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the fourth quarter 2021
Revenue in fourth quarter ended at MNOK 78 compared to MNOK 64 in Q4 2020. The revenue increase was driven by higher sales volume (+29%) and sales prices, partly offset by a significant stronger NOK vs EUR compared to last year.
Fourth quarter EBITDA ended at MNOK 12.2 (Q4’20: MNOK 13.9) a 13% decrease compared to similar quarter last year. The lower EBITDA in Q4’21 was driven by a stronger NOK vs EUR, increased raw material prices, record high international freight costs, bonus accrual and significantly higher electricity prices in the quarter compared to last year. Currency neutral EBITDA in Q4’21 compared to Q4’20 shows an increase of approx. 15%.
The net profit for the group ended at MNOK 7.2 (Q4’20: MNOK 8.6) for the fourth quarter of 2021.
Vistin Pharma had cash of MNOK 36 (Q4’20 MNOK: 77) as of 31 December 2021. Approx. 55% of the Metformin Expansion Project (MEP) has been paid as of end December. The company has a strong balance sheet with an equity ratio of 83% and no interest-bearing debt.
2021 had an all-time high sales volume of 3 748MT compared to 3 360MT in 2020, an increase of 12%.
The fourth quarter conference call, which will be held today, 17th of February, at 8.30am (CET) will be available via web and audio through the following access points:
Telephone conference:
Confirmation Code: 7590346
International dial-In: +44 (0) 2071 928338
Norway, Oslo: +47 21563015
United States, New York: +1 6467413167
Webcast:
https://edge.media-server.com/mmc/p/jb9o62eq
The conference call will be held in English.
Please find the Q4 report and presentation enclosed. The report will also be made available on www.vistin.com.
*****
For further information, please contact:
Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.